Author + information
- Marcos Ortega1,
- Paulino Quiñonez2,
- Marcelo Medrano3,
- Cesar Chavez4,
- Ernesto Del Pino5 and
- Jose Costa Jr.6
- 1HOSPITAL IESS, Guayaquil, Ecuador
- 2Hospital Teodoro Maldonado Carbo, Guayaquil, Ecuador
- 3Institito de Cadiologia de Belgorod, Belgorod, Russian Federation
- 4Teodoro Maldonado Carbo, Guayaquil, Ecuador
- 5Hospital Teodoro Maldonado Carbo, Guayaquil, Ecuador
- 6Cardiovascular Research Center, São Paulo, São Paulo, Brazil
Safety concerns with 1st generation of bioabsorbable vascular scaffolds(BRS) have prompted the development of next generation of these devices, focused on thinner struts and faster resorption time. Recently developed, the MeRes100 (Meril Life Sciences) is a sirolimus-eluting (1.25 mg/mm2) BRS, which is built of a thin-strut (100mm) PLLA polymer with a hybrid cell design (closed cells on the edges and open cells on the center). There are couplets of tri-axial radiopaque markets at either end to facilitate scaffold positioning and post dilation. Bioresorption is expected to occur within 2 years.We sought to evaluate the performance of this device in the treatment of “real-world”, less selected patients.
A propective, single center registry including patients treated between August 2016 and April 2018. Exclusion criteria were: cardiogenic shock, in stent restenosis and target lesions at left main/ bypass graft. BRS were available in 2.5 to 3.5m and up to 40mm in length. All procedures were guided by OCT. Primary endpoints included procedure success and one-year MACE rate. Nine-month OCT assessment is part of the secondary endpoints.
A total of 65 patients underwent PCI with 81 MeRes100. Most patients were male (86%), with mean age of 66yo and 41% of diabetes. Non ST elevation MI was the initial clinical presentation in 23% of the cases, while LAD was the most frequent target vessel (46%). Device success was achieved in 98% of the cases. In the in-hospital phase, MACE rate was 0%. During the clinical follow-up period, a single case of BRS thrombosis(1.5%) was observed, in a patient who discontinued DAPT in the 1st month after the procedure. At one year, total MACE rate was 4%, with 4% of ischemia-driven TLR.
Our initial “real-world” experience with the novel MERES 100 showed excellent acute performance with low and acceptable one year MACE and device thrombosis rates. Later clinical follow-up and OCT analysis will shed more light into these preliminary findings.
CORONARY: Stents: Bioresorbable Vascular Scaffolds